About GliaMed

About company

GliaMed is a development-stage biopharmaceutical company dedicated to the discovery and development of small molecule drugs which enhance the human body’s innate ability to regenerate. Founded in 2001, the company is focused on the development of compounds termed Regenerative Immunophilin Ligands or RILs. In preclinical models, treatment with RILs has been shown to induce the localized expression of transcription factors characteristic of pluripotent stem cells at the site of acute disease or trauma.